Digoxin‐associated decrease in parathyroid hormone (<scp>PTH</scp>) concentrations in patients with atrial fibrillation

Apel, Arie; Pauzner, Rachel; Cohen, Ohad; Mayan, Haim

doi:10.1111/eci.12026

Cited by 4 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies investigated the implications of biomarkers such as TGF-β1, ferritin, PTH, CA -125, micro RNAs, N-terminal pro-B type natriuretic peptide (NT-proBNP), and b type natriuretic peptide (BNP) as a surrogate marker of fibrosis in AF patients [18][19][20][21][22]. Also, FGF-21 and FGF-23, members of the fibroblast growth factor family, were evaluated in previous studies for their levels in patients with AF [23,24].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Atrial Fibrosis in Atrial Fibrillation Patients with Three Different Methods

2021

Turk J Med Sci

View full text Add to dashboard Cite

BackgroundThe presence of atrial fibrosis has already been known as a risk factor for atrial fibrillation (AF) development. ObjectiveWe aimed to evaluate atrial fibrosis with previously defined three different methods, which were cardiac magnetic resonance imaging (C-MRI), echocardiographic strain imaging, and biomarkers, and show the relationship between these methods, in patients with AF scheduled for cryoballoon ablation. Method30 patients were enrolled. Atrial T1 relaxation durations were measured using C-MRI before the procedure of atrial fibrillation catheter ablation. Fibroblast growth factor-21 (FGF-21) and fibroblast growth factor-23 (FGF-23) levels were measured at serum derived from the femoral artery (Peripheral FGF 21 and 23) and left atrium blood samples (Central FGF 21 and 23) before catheter ablation.Preprocedural transthoracic echocardiography was performed. The Median follow-up duration for atrial tachyarrhythmia (ATa) recurrence was 13 (12-18 months) months. ResultsThe mean ages of the study group were 55.23 ± 12.37 years and there were 17 (56.7%) female patients in study population. There were negative correlations between post contrast T1 relaxation durations of both posterior and

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Atrial Fibrosis in Atrial Fibrillation Patients with Three Different Methods

2021

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials

et al. 2013

View full text Add to dashboard Cite

Cardiac glycosides have a long history in the treatment of cardiac disease. However, several preclinical studies as well as two phase I studies have shown that cardenolides may also possess anticancer effects. The mechanisms of these anticancer effects may include intracellular decrease of K(+) and increase of Na(+) and Ca(2+); intracellular acidification; inhibition of IL-8 production and of the TNF-α/NF-κB pathway; inhibition of DNA topoisomerase II and activation of the Src kinase pathway. To date three cardiac glycosides have been developed for treatment of cancer and were tested in a phase 1 clinical trial to determine dose limiting toxicities and maximum tolerated dose. Future studies of this novel class of anticancer drugs are warranted to determine their possible role in cancer treatment.

show abstract

Ameliorative potential of vitamin P and digoxin in ischemic–reperfusion induced renal injury using the Langendorff apparatus

Muthuraman

Kaur

et al. 2015

Life Sciences

View full text Add to dashboard Cite

Digoxin‐associated decrease in parathyroid hormone (PTH) concentrations in patients with atrial fibrillation

Abstract: Although the patients were normocalcemic, plasma PTH concentrations decreased with digoxin treatment. The effect of the sodium pump on PTH secretion might be important in human PTH homoeostasis and might be a potential target for the treatment of disturbances in calcium homoeostasis.

Cited by 4 publications

References 24 publications

Evaluation of Atrial Fibrosis in Atrial Fibrillation Patients with Three Different Methods

Evaluation of Atrial Fibrosis in Atrial Fibrillation Patients with Three Different Methods

Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials

Ameliorative potential of vitamin P and digoxin in ischemic–reperfusion induced renal injury using the Langendorff apparatus

Contact Info

Product

Resources

About